Age-related changes in pharmacokinetics

Current Drug Metabolism

Volumn 12, Issue 7, 2011, Pages 601-610

  Shi, Shaojun ^a   Klotz, Ulrich ^b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clearance; Cytochrome P450; Elderly; Metabolism; Pharmacokinetics; Transporter

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BUPRENORPHINE; CARRIER PROTEIN; CELECOXIB; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DIAZEPAM; DICLOFENAC; DIGOXIN; ENALAPRIL; FENTANYL; FLUOXETINE; LABETALOL; MIDAZOLAM; OMEPRAZOLE; PERINDOPRIL; PROPAFENONE; PROPRANOLOL; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

AGE; AGING; BODY FAT; BODY WATER; CARDIOVASCULAR DISEASE; COMORBIDITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FIRST PASS EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHILICITY; KIDNEY FUNCTION; LEAN BODY WEIGHT; LIPOPHILICITY; PHARMACODYNAMICS; POLYPHARMACY; REVIEW; RISK FACTOR;

AGED; AGING; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYPHARMACY;

EID: 79961084008     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011796504527     Document Type: Review

References (126)

1. United Nations. World Population Aging 2009. Available at: http://www.un.org/esa/population/publications/WPA2009/WPA2009-WorkingPaper.pdf. (Accessed August 8, 2010)
2. Balducci, L. Aging, frailty, and chemotherapy. Cancer Control, 2007,14(1), 7-12. (Pubitemid 46168961)
3. Abizanda Soler, P.; Paterna Mellinas, G.; Martínez Sánchez, E.; López Jiménez, E. Comorbidity in the elderly: Utility and validity of assessment tools. Rev. Esp. Geriatr. Gerontol., 2010, 45(4), 219-228.
4. Maeda, K. Systematic review of the effects of improvement of prescription to reduce the number of medications in the elderly with polypharmacy. Yakugaku Zasshi, 2009, 129(5), 631-645.
5. Pizzuti, R.; Caffari, B.; Binkin, N.; Gruppo ARGENTO. Prescription drugs and the elderly: results of the Argento study. Ig. Sanita. Pubbl., 2006, 62(1), 11-26.
6. Lam, D.P.; Mak, C.F.; Chan, S.M.; Yao, R.W.; Leung, S.S.; You, J.H. Polypharmacy and inappropriate prescribing in elderly Hong Kong Chinese patients. Am. Geriatr. Soc., 2010, 58(1), 203-205.
7. Müller, M. Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria. Wien. Klin. Wochenschr., 2008, 120(23- 24), 713-714.
8. Cooney, D.; Pascuzzi, K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin. Geriatr. Med., 2009, 25(2), 221-233.
9. Kalula, S.Z. Drugs and the older person. CME., 2007, 25(9), 422-425.
10. Polidoro, A.; Dornbusch, T.; Vestri, A.; Di Bona, S.; Alessandri, C. Frailty and disability in the elderly: A diagnostic dilemma. Arch. Gerontol. Geriatr., 2011, 52(2), e75-e78.
11. Hubbard, R.E.; Woodhouse, K.W. Frailty, inflammation and the elderly. Biogerontology, 2010, 11(5), 635-641.
12. Shi, S.; Mörike, K.; Klotz, U. The clinical implications of ageing for rational drug therapy. Eur. J. Clin. Pharmacol., 2008, 64(2), 183-199.
13. Bergkvist, A.; Midlöv, P.; Höglund, P.; Larsson, L.; Eriksson, T. A multi-intervention approach on drug therapy can lead to a more appropriate drug use in the elderly. LIMM-Landskrona Integrated Medicines Management. J. Eval. Clin. Pract., 2009, 15(4), 660-667.
14. Bruhn, C. Drug therapy for the elderly: what should be considered? Dtsch. Med. Wochenschr., 2010, 135(17), p16.
15. Klotz, U. Pharmacokinetics and drug metabolism in the elderly. Drug. Metab. Rev., 2009, 41(2), 67-76.
16. Hilmer, S.N.; McLachlan, A.J.; Le Couteur, D.G. Clinical pharmacology in the geriatric patient. Fundam. Clin. Pharmacol., 2007, 21(3), 217-230. (Pubitemid 46804936)
17. Delafuente, J.C. Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. Consult. Pharm., 2008, 23(4), 324-334. (Pubitemid 351738239)
18. Aymanns, C.; Keller, F.; Maus, S.; Hartmann, B.; Czock, D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin. J. Am. Soc. Nephrol., 2010, 5(2), 314-327.
19. Corsonello, A.; Pedone, C.; Incalzi, R.A. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr. Med. Chem., 2010, 17(6), 571-584.
20. Goldacre, M.J. Demography of aging and the epidemiology of gastrointestinal disorders in the elderly. Best. Pract. Res. Clin. Gastroenterol., 2009, 23(6), 793-804.
21. Bhutto, A.; Morley, J.E. The clinical significance of gastrointestinal changes with aging. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(5), 651-660.
22. Salles, N. Basic mechanisms of the aging gastrointestinal tract. Dig. Dis., 2007, 25(2), 112-117. (Pubitemid 46663776)
23. Orr, W.C.; Chen, C.L. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 283(6), G1226-G1231. (Pubitemid 35351108)
24. Madsen, J.L.; Graff, J. Effects of aging on gastrointestinal motor function. Age Aging, 2004, 33(2), 154-159. (Pubitemid 38313114)
25. Shimamoto, C.; Hirata, I.; Hiraike, Y.; Takeuchi, N.; Nomura, T.; Katsu, K. Evaluation of gastric motor activity in the elderly by electrogastrography and the (13) C-acetate breath test. Gerontology, 2002, 48(6), 381-386. (Pubitemid 36152989)
26. Hurwitz, A.; Brady, D.A.; Schaal, S.E.; Samloff, I.M.; Dedon, J.; Ruhl, C.E. Gastric acidity in older adults. JAMA., 1997, 278(8), 659-662. (Pubitemid 27373840)
27. Haruma, K.; Kamada, T.; Kawaguchi, H.; Okamoto, S.; Yoshihara, M.; Sumii, K.; Inoue, M.; Kishimoto, S.; Kajiyama, G.; Miyoshi, A. Effect of age and Helicobacter pylori infection on gastric acid secretion.Gastroenterol. Hepatol., 2000, 15(3), 277-283. (Pubitemid 30190741)
28. Iijima, K.; Ohara, S.; Koike, T.; Sekine, H.; Shimosegawa, T. Gastric acid secretion of normal Japanese subjects in relation to Helicobacter pylori infection, aging, and gender. Scand. J. Gastroenterol., 2004, 39(8), 709-716. (Pubitemid 39093242)
29. Ciccocioppo, R.; Di Sabatino, A.; Luinetti, O.; Rossi, M.; Cifone, M.G.; Corazza, G.R. Small bowel enterocyte apoptosis and proliferation are increased in the elderly. Gerontology., 2002, 48(4), 204-208. (Pubitemid 34621616)
30. Saltzman, J.R.; Kowdley, K.V.; Perrone, G.; Russell, R.M. Changes in small-intestine permeability with aging. J. Am. Geriatr. Soc., 1995, 43(2), 160-164.
31. Dobson, P.D.; Lanthaler, K.; Oliver, S.G.; Kell, D.B. Implications of the dominant role of transporters in drug uptake by cells. Curr. Top. Med. Chem., 2009, 9(2), 163-181.
32. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G.F.; Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernaes, H.; Senner, F. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov., 2010, 9(8), 597-614
33. Dobson, P.D.; Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov., 2008, 7(3), 205-220. (Pubitemid 351321232)
34. McLean, A.J.; Le Couteur, D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev., 2004, 56(2), 163-184. (Pubitemid 38720828)
35. Zeeh, J.; Platt, D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology, 2002, 48(3), 121-127. (Pubitemid 34310065)
36. Tateishi, T.; Fujimura, A.; Shiga, T.; Ohashi, K.; Ebihara, A. Influence of aging on the oxidative and conjugative metabolism of propranolol. Int. J. Clin. Pharmacol. Res., 1995, 15(3), 95-101.
37. Anantharaju, A.; Feller, A.; Chedid, A. Aging Liver. A review. Gerontology, 2002, 48(6), 343-353.
38. Fromm, M.F.; Dilger, K.; Busse, D.; Kroemer, H.K.; Eichelbaum, M.; Klotz, U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br. J. Clin. Pharmacol., 1998, 45(3), 247-255. (Pubitemid 28081920)
39. Dilger, K.; Hofmann, U.; Klotz, U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin. Pharmacol. Ther., 2000, 67(5), 512-520. (Pubitemid 30327490)
40. Davies, R.O.; Gomez, H.J.; Irvin, J.D.; Walker, J.F. An overview of the clinical pharmacology of enalapril. Br. J. Clin. Pharmacol., 1984, 18 (Suppl 2), 215S-229S. (Pubitemid 15128835)
41. Muriel Villoria, C.; Pérez-Castejón Garrote, J.M.; Sánchez Magro, I.; Neira Alvarez, M. Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study. Med. Clin (Barc)., 2007, 128(6), 204-210.
42. Vadivelu, N.; Hines, R.L. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin. Interv. Aging, 2008, 3(3), 421-430.
43. Ramsay, S.E.; Whincup, P.H.; Shaper, A.G.; Wannamethee, S.G. The relations of body composition and adiposity measures to ill health and physical disability in elderly men. Am. J. Epidemiol., 2006, 164(5), 459-469. (Pubitemid 44576613)
44. Elmadfa, I.; Meyer, A.L. Body composition, changing physiological functions and nutrient requirements of the elderly. Ann. Nutr. Metab., 2008, 52(Suppl 1), 2-5. (Pubitemid 351496696)
45. St-Onge, M.P.; Gallagher, D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition, 2010, 26(2),152-155.
46. Hanratty, C.G.; McGlinchey, P.; Johnston, G.D.; Passmore, A.P. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging, 2000, 17(5), 353-362.
47. Klotz, U.; Avant, G.R.; Hoyumpa, A.; Schenker, S.; Wilkinson, G.R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. Clin. Invest., 1975, 55(2), 347-359.
48. Mörike, K.; Schwab, M.; Klotz, U. Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging, 1997, 10(4), 259-277.
49. Butler, J.M.; Begg, E.J. Free drug metabolic clearance in elderly people. Clin. Pharmacokinet., 2008, 47(5), 297-321. (Pubitemid 351508117)
50. Benet, L.Z.; Hoener, B.A. Changes in plasma protein binding have little clinical relevance. Clin, Pharmacol, Ther., 2002, 71(3), 115-121. (Pubitemid 34271114)
51. Benedetti, M.S.; Whomsley, R.; Poggesi, I.; Cawello, W.; Mathy, F.X.; Delporte, M.L.; Papeleu, P.; Watelet, J.B. Drug metabolism and pharmacokinetics. Drug Metab. Rev., 2009, 41(3), 344-390.
52. Endres, C.J.; Endres, M.G.; Unadkat, J.D. Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol. Pharm., 2009, 6(6), 1756-1765.
53. Zhang, L.; Zhang, Y.; Huang, S.M. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol. Pharm., 2009, 6(6), 1766-1774.
54. Wynne, H. Drug metabolism and ageing. J. Br. Menopause. Soc., 2005, 11(2), 51-56. (Pubitemid 40872876)
55. Warren, A.; Chaberek, S.; Ostrowski, K.; Cogger, V.C.; Hilmer, S.N.; McCuskey, R.S.; Fraser, R.; Le Couteur, D.G. Effects of old age on vascular complexity and dispersion of the hepatic sinusoidal network. Microcirculation, 2008, 15(3), 191-202.
56. Frith, J.; Jones, D.; Newton, J.L. Chronic liver disease in an ageing population. Age Ageing, 2009, 38(1), 11-18.
57. Herrlinger, C.; Klotz, U. Drug metabolism and drug interactions in the elderly. Best Pract. Res. Clin. Gastroenterol., 2001, 15(6), 897-918. (Pubitemid 34110600)
58. Le Couteur, D.G.; McLean, A.J. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin. Pharmacokinet., 1998, 34(5), 359-373. (Pubitemid 28192906)
59. Schmucker, D.L. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging, 2001, 18(11), 837-851. (Pubitemid 34073129)
60. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423. (Pubitemid 24229655)
61. Hunt, C.M.; Westerkam, W.R.; Stave, G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol., 1992, 44(2), 275-283.
62. Hubbard, R.E.; O'Mahony, M.S.; Calver, B.L.; Woodhouse, K.W. Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol., 2008, 64(9), 895-900.
63. Parkinson, A.; Mudra, D.R.; Johnson, C.; Dwyer, A.; Carroll, K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol., 2004, 199(3), 193-209. (Pubitemid 39208721)
64. Wauthier, V.; Verbeeck, R.K.; Calderon, P.B. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr. Med. Chem., 2007, 14(7), 745-757. (Pubitemid 46477709)
65. Kinirons, M.T.; O'Mahony, M.S. Drug metabolism and ageing. Br. J. Clin. Pharmacol., 2004, 57(5), 540-544. (Pubitemid 38582172)
66. Wynne, H. Drug metabolism and ageing. J. Br. Menopause. Soc., 2005, 11(2), 51-56. (Pubitemid 40872876)
67. Frassetto, L.A.; Poon, S.; Tsourounis, C.; Valera, C.; Benet, L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther., 2007, 81(6), 828-832. (Pubitemid 46788293)
68. Kurnik, D.; Wood. A.J.; Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther., 2006, 80(3), 228-234. (Pubitemid 44301092)
69. Schwartz, J.B. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin. Pharmacol. Ther., 2006, 79(5), 440-448.
70. Kirwan, C.; MacPhee, I.; Philips, B. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? Expert Opin. Drug Metab. Toxicol., 2010, 6(6), 761-771.
71. Greenblatt, D.J.; Abernethy, D.R.; Locniskar, A.; Harmatz, J.S.; Limjuco, R.A.; Shader, R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology, 1984, 61(1), 27-35. (Pubitemid 14089351)
72. Platten, H.P.; Schweizer, E.; Dilger, K.; Mikus, G.; Klotz, U. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin. Pharmacol. Ther., 1998, 63(5), 552-560. (Pubitemid 28277276)
73. Albrecht, S.; Ihmsen, H.; Hering, W.; Geisslinger, G.; Dingemanse, J.; Schwilden, H.; Schüttler, J. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin. Pharmacol. Ther., 1999, 65(6), 630-639. (Pubitemid 29294026)
74. Cabrera, M.A.; Dip, R.M.; Furlan, M.O.; Rodrigues, S.L. Use of drugs that act on the cytochrome P450 system in the elderly. Clinics (Sao Paulo), 2009, 64(4), 273-278.
75. Klotz, U.; Schwab, M.; Treiber, G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol., 2004, 95(1), 2-8. (Pubitemid 38993131)
76. Shi, S.; Klotz, U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol., 2008, 64(10), 935-951.
77. Ishizawa, Y.; Yasui-Furukori, N.; Takahata, T.; Sasaki, M.; Tateishi, T. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin. Pharmacokinet., 2005, 44(11), 1179-1189. (Pubitemid 41483702)
78. Harvey, A.T.; Preskorn, S.H. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J. Clin. Psychopharmacol., 2001, 21(2), 161-166. (Pubitemid 32221053)
79. Pautas, E.; Moreau, C.; Gouin-Thibault, I.; Golmard, J.L.; Mahé, I.; Legendre, C.; Taillandier-Hériche, E.; Durand-Gasselin, B.; Houllier, A.M.; Verrier, P.; Beaune, P.; Loriot, M.A.; Siguret, V. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther., 2010, 87(1), 57-64.
80. Klotz, U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin. Pharmacokinet., 2007, 46(4), 271-279. (Pubitemid 46507006)
81. Shi, S.; Klotz, U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol., 2008, 64(3), 233-252.
82. Brenner, S.S.; Herrlinger, C.; Dilger, K.; Mürdter, T.E.; Hofmann, U.; Marx, C.; Klotz, U. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet., 2003, 42(3), 283-292. (Pubitemid 36308065)
83. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48(11), 689-723.
84. Doki, K.; Homma, M.; Kuga, K.; Aonuma, K.; Kohda, Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br. J. Clin. Pharmacol., 2009, 68(1), 89-96.
85. Orlando, R.; De Martin, S.; Andrighetto, L.; Floreani, M.; Palatini, P. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. Br. J. Clin. Pharmacol., 2010, 69(3), 279-286.
86. Draper, B.; Berman, K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging, 2008, 25(6), 501-519. (Pubitemid 351812258)
87. Walter-Sack, I.; Klotz, U. Influence of diet and nutritional status on drug metabolism. Clin. Pharmacokinet., 1996, 31(1), 47-64. (Pubitemid 26238202)
88. Klotz, U. Effect of aging on the pharmacokinetics of gastrointestinal drugs. In: Pilotti A, Malferthheiner P, Holt PR(eds.), Aging and the Gastrointestinal Tract. Interdisciplinary Topics in Gerontology. Basel, Switzerland: Karger, 2003; Vol. 32, pp. 28-39.
89. Villesen, H.H.; Banning, A.M.; Petersen, R.H.; Weinelt, S.; Poulsen, J.B.; Hansen, S.H.; Christrup, L.L. Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. Ther. Clin. Risk Manag., 2007, 3(5), 961-967. (Pubitemid 350162094)
90. Scherrmann, J.M. Transporters in absorption, distribution, and elimination. Chem. Biodivers, 2009, 6(11), 1933-1942.
91. Shugarts, S.; Benet, L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res., 2009, 26(9), 2039-2054.
92. Mangoni, A.A. The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 315-320.
93. Li, Y.; Yuan, H.; Yang, K.; Xu, W.; Tang, W.; Li, X. The structure and functions of P-glycoprotein. Curr. Med. Chem., 2010, 17(8), 786-800.
94. Roberts, D.J.; Goralski, K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin. Drug Metab. Toxicol., 2008, 4(10), 1245-1264.
95. Brenner, S.S.; Klotz, U. P-glycoprotein function in the elderly. Eur. J. Clin. Pharmacol., 2004, 60(2), 97-102. (Pubitemid 38626438)
96. Bartels, A.L.; Kortekaas, R.; Bart, J.; Willemsen, A.T.; de Klerk, O.L.; de Vries, J.J.; van Oostrom, J.C.; Leenders, K.L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging, 2009, 30(11), 1818-1824.
97. Kaiser, M.; Bandinelli, S.; Lunenfeld, B. Frailty and the role of nutrition in older people. A review of the current literature. Acta. Biomed., 2010, 81(Suppl 1), 37-45.
98. Karunananthan, S.; Wolfson, C.; Bergman, H.; Béland, F.; Hogan, D.B. A multidisciplinary systematic literature review on frailty: overview of the methodology used by the Canadian Initiative on Frailty and Aging. BMC. Med. Res. Methodol., 2009, 9, 68.
99. Klotz, U. The elderly-a challenge for appropriate drug treatment. Eur. J. Clin. Pharmacol., 2008, 64(3), 225-226.
100. Abou-Hatab, K.; O'Mahony, M.S.; Patel, S.; Carey, D.; Woodhouse, K. Plasma esterase activities in young and old patients undergoing open inguinal hernia repair. Arch. Gerontol. Geriatr., 2000, 31(3), 193-198. (Pubitemid 32012632)
101. Abou-Hatab, K.; Ganeshalingam, K.; O'Mahony, M.S.; Giurani, F.; Patel, S.; Woodhouse, K. The effect of community-acquired pneumonia on plasma esterases in older people. Eur. J. Clin. Pharmacol., 2001, 57(1), 55-60. (Pubitemid 32391414)
102. Lindeman, R.D.; Tobin, J.; Shock, N.W. Longitudinal studies on the rate of decline in renal function with age. J. Am. Geriatr. Soc., 1985, 33(4), 278-285. (Pubitemid 15087125)
103. Froissart, M.; Rossert, J. How to improve estimation of renal function in the elderly. Rev. Prat., 2005, 55(20), 2223-2229. (Pubitemid 43067088)
104. Fliser, D.; Franek, E.; Joest, M.; Block, S.; Mutschler, E.; Ritz, E. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int., 1997, 51(4), 1196-1204. (Pubitemid 27186546)
105. Fliser, D.; Franek, E.; Ritz, E. Renal function in the elderly-is the dogma of an inexorable decline of renal function correct? Nephrol. Dial. Transplant., 1997, 12(8), 1553-1555. (Pubitemid 27346273)
106. Baggio, B.; Budakovic, A.; Perissinotto, E.; Maggi, S.; Cantaro, S.; Enzi, G.; Grigoletto, F.; ILSA Working Group. Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA). Nephrol. Dial. Transplant., 2005, 20(1), 114-123. (Pubitemid 40207615)
107. Odden, M.C.; Shlipak, M.G.; Tager, I.B. Serum creatinine and functional limitation in elderly persons. J. Gerontol. A. Biol. Sci. Med. Sci., 2009, 64(3), 370-376.
108. Corsonello, A.; Pedone, C.; Corica, F.; Mussi, C.; Carbonin, P.; Antonelli Incalzi, R.; Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA) Investigators Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch. Intern. Med., 2005, 165(7), 790-795. (Pubitemid 40569433)
109. Gómez Carracedo, A.; Baztán Cortés, J.J. Renal function evaluation methods in the elderly: reliability and clinical implications. Rev. Esp. Geriatr. Gerontol., 2009, 44(5), 266-272.
110. Laroche, M.L.; Charmes, J.P.; Marcheix, A.; Bouthier, F.; Merle, L. Estimation of glomerular filtration rate in the elderly: Cockcroft- Gault formula versus modification of diet in renal disease formula. Pharmacotherapy, 2006, 26(7), 1041-1046.
111. Lamb, E.J.; Webb, M.C.; O'Riordan, S.E. Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people. Age Ageing, 2007, 36(6), 689-692. (Pubitemid 350258982)
112. Helldén, A.; Bergman, U.; von Euler, M.; Hentschke, M.; Odar-Cederlöf, I.; Ohlén, G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study. Drugs Aging, 2009, 26(7), 595-606.
113. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F. 3rd.; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; Coresh, J.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med., 2009, 150(9), 604-612.
114. Stevens, L.A.; Schmid, C.H.; Greene, T.; Zhang, Y.L.; Beck, G.J.; Froissart, M.; Hamm, L.L.; Lewis, J.B.; Mauer, M.; Navis, G.J.; Steffes, M.W.; Eggers, P.W.; Coresh, J.; Levey, A.S. Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m(2). Am. J. Kidney Dis., 2010, 56(3), 486-495.
115. Hojs, R.; Bevc, S.; Ekart, R.; Gorenjak, M.; Puklavec, L. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin. Nephrol., 2008, 70(1), 10-17. (Pubitemid 352005965)
116. Qutb, A.; Syed, G.; Tamim, H.M.; Al Jondeby, M.; Jaradat, M.; Tamimi, W.; Al Ghamdi, G.; Al Qurashi, S.; Flaiw, A.; Hejaili, F.; Al Sayyari, A.A. Cystatin C-based formula is superior to MDRD, Cockcroft-Gault and Nankivell formulae in estimating the glomerular filtration rate in renal allografts. Exp. Clin. Transplant., 2009, 7(4), 197-202.
117. Fliser, D. Assessment of renal function in elderly patients. Curr. Opin. Nephrol. Hypertens., 2008, 17(6), 604-608.
118. Sproule, B.A.; Hardy, B.G.; Shulman, K.I. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging, 2000, 16(3), 165-177. (Pubitemid 30166918)
119. Patat, A.; Parks, V.; Raje, S.; Plotka, A.; Chassard, D.; Le Coz, F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br. J. Clin. Pharmacol., 2009, 67(3), 299-308.
120. Perucca, E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet., 2006, 45(4), 351-363.
121. Perucca, E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int. Rev. Neurobiol., 2007, 81, 183-199.
122. Goldberg, M.R.; Wong, S.L.; Shaw, J.P.; Kitt, M.M.; Barriere, S.L. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy, 2010, 30(8), 806-811.
123. Malhotra, B.K.; Wood, N.; Sachse, R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int. J. Clin. Pharmacol. Ther., 2009, 47(9), 570-578.
124. Vik, S.A.; Hogan, D.B.; Patten, S.B.; Johnson, J.A.; Romonko- Slack, L.; Maxwell, C.J. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging, 2006, 23(4), 345-356. (Pubitemid 43830665)
125. Page, R.L. 2nd.; Linnebur, S.A.; Bryant, L.L.; Ruscin, J.M. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin. Interv. Aging, 2010, 5, 75-87.
126. Pang, K.S.; Maeng, H.J.; Fan, J. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm., 2009, 6(6), 1734-1755.